INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

StatusNot Yet Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Beijing Tiantan Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 4 more changesShow less
    • Start date: Feb 1, 2026 to Sep 8, 2026
    • Eligibility criteria expanded, about 81 words
    • Secondary endpoints: details revised at 10 of 17 entries
    • Study description revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Beijing Tiantan Hospital
281 trials monitored
See 10 trials at risk
Stroke
3,537 trials monitored
See 161 trials at risk
The research team is conducting a randomized, double-blind, placebo-controlled, multicenter clinical study aimed at evaluating the impact of adding Tolecilimab (a PCSK9 inhibitor) to standard lipid-lowering therapy (statins ± ezetimibe) on serum lipoprotein(a) \[Lp(a)\] levels and the risk of stroke recurrence within 90 days in patients with ischemic stroke or high-risk TIA (ABCD² ≥ 4) accompanied by elevated lipoprotein(a) levels (≥30 mg/dL).
Trial Details
NCT Number NCT07341958
Lead Sponsor Beijing Tiantan Hospital
Conditions
(from sponsor)		 Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Related terms Ischemic Stroke
Enrollment 242 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov